In this study we are evaluating the safety and feasibility of the triple combination (TTFields, MLA, pembrolizumab) in adult patients diagnosed with recurrent or progressive glioblastoma (GBM) WHO Grade IV, IDH wild type or recurrent or progressive…
- Investigator
- Ashley Ghiaseddin
- Ages
- 18 Years - 90 Years
- Sexes
- All